| For: | Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy. World J Gastroenterol 2015; 21(39): 11168-11178 [PMID: 26494971 DOI: 10.3748/wjg.v21.i39.11168] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i39/11168.htm |
| Number | Citing Articles |
| 1 |
Saunjoo L. Yoon, Oliver Grundmann, Sherise Rogers, Judith M. Schlaeger, Bo Han, Edward Agyare, Diana J. Wilkie. Cachexia in Pancreatic Cancer: New Insights to Impact Quality of Life and Survival. Nutrients 2025; 17(19) doi: 10.3390/nu17193064
|
| 2 |
Shiyu Tong, Xiheng Hu, Yangle Li. Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle–invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations 2022; 40(9) doi: 10.1016/j.urolonc.2022.05.020
|
| 3 |
Liang Liu, Jun-Hui He, Yu Xiao, Dong Wei. Prognostic impact of serum interleukin-6 and 17 level in patients with bladder cancer: a systematic review and meta-analysis. PeerJ 2025; 13 doi: 10.7717/peerj.19385
|
| 4 |
Gregory P. Takacs, Joseph A. Flores-Toro, Jeffrey K. Harrison. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy. Pharmacology & Therapeutics 2021; 222 doi: 10.1016/j.pharmthera.2020.107790
|
| 5 |
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho, Ali-Akbar Delbandi. Current and future immunotherapeutic approaches in pancreatic cancer treatment. Journal of Hematology & Oncology 2024; 17(1) doi: 10.1186/s13045-024-01561-6
|
| 6 |
Daniel Netto, Melissa Frizziero, Victoria Foy, Mairéad G. McNamara, Alison Backen, Richard A. Hubner. Systemic Therapy for Metastatic Pancreatic Cancer—Current Landscape and Future Directions. Current Oncology 2024; 31(9) doi: 10.3390/curroncol31090385
|
| 7 |
Jing Peng, Supradeep Madduri, Angela D. Clontz, Delisha A. Stewart. Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1106520
|
| 8 |
Heather L. Lewis, Jeff M. Chakedis, Erin Talbert, Ericka Haverick, Priyani Rajasekera, Philip Hart, Mark Bloomston, Mary Dillhoff, Timothy M. Pawlik, Denis Guttridge, Carl R. Schmidt. Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma. Journal of Surgical Oncology 2018; 117(6) doi: 10.1002/jso.24940
|
| 9 |
Noomi Vainer, Christian Dehlendorff, Julia S. Johansen. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget 2018; 9(51) doi: 10.18632/oncotarget.25661
|
| 10 |
Meihui Song, Ying Tang, Kaimei Cao, Ling Qi, Keping Xie. Unveiling the role of interleukin-6 in pancreatic cancer occurrence and progression. Frontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1408312
|
| 11 |
Manzoor Ahmad Mir, Aanisa Ishrat, Nusrat Jan. Cytokine and Chemokine Networks in Cancer. 2023; doi: 10.1007/978-981-99-4657-0_13
|
| 12 |
Kanan Panchal, Rakesh Kumar Sahoo, Umesh Gupta, Akash Chaurasiya. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. International Immunopharmacology 2021; 95 doi: 10.1016/j.intimp.2021.107508
|
| 13 |
Abhishek D. Garg, Monica Vara Perez, Marco Schaaf, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. Trial watch: Dendritic cell-based anticancer immunotherapy. OncoImmunology 2017; doi: 10.1080/2162402X.2017.1328341
|
| 14 |
Vlad-Vasile Pop, Andrada Seicean, Iulia Lupan, Gabriel Samasca, Claudia-Cristina Burz. IL-6 roles – Molecular pathway and clinical implication in pancreatic cancer – A systemic review. Immunology Letters 2017; 181 doi: 10.1016/j.imlet.2016.11.010
|
| 15 |
|
| 16 |
Ha Thi Thu Do, Chang Hoon Lee, Jungsook Cho. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. Cancers 2020; 12(2) doi: 10.3390/cancers12020287
|
| 17 |
Eduard Achim, Elena Pîrlici, Cecilia Cristea, Mihaela Tertis. Design and Efficacy of Oncolytic Viruses and Antitumor Vaccines: A Dead End in the Immunotherapy of Pancreatic Cancer?. International Journal of Molecular Sciences 2025; 26(19) doi: 10.3390/ijms26199640
|
| 18 |
Chao Yin, Ali Alqahtani, Marcus S. Noel. The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. Cancers 2022; 14(11) doi: 10.3390/cancers14112619
|
| 19 |
Anton Deicher, Roland Andersson, Bobby Tingstedt, Gert Lindell, Monika Bauden, Daniel Ansari. Targeting dendritic cells in pancreatic ductal adenocarcinoma. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0585-0
|
| 20 |
Mikio Kajihara, Kazuki Takakura, Tomoya Kanai, Zensho Ito, Yoshihiro Matsumoto, Shigetaka Shimodaira, Masato Okamoto, Toshifumi Ohkusa, Shigeo Koido. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. World Journal of Gastroenterology 2016; 22(18): 4446-4458 doi: 10.3748/wjg.v22.i18.4446
|
| 21 |
Shigeo Koido, Masato Okamoto, Shigetaka Shimodaira, Haruo Sugiyama. Wilms’ Tumor 1 (WT1)-Targeted Cancer Vaccines To Extend Survival for Patients with Pancreatic Cancer. Immunotherapy 2016; 8(11) doi: 10.2217/imt-2016-0031
|
| 22 |
Marta Łukaszewicz-Zając, Mariusz Gryko, Barbara Mroczko. The role of selected chemokines and their specific receptors in pancreatic cancer. The International Journal of Biological Markers 2018; 33(2) doi: 10.1177/1724600817753094
|
| 23 |
Na Song, Kai Cui, Liqun Zeng, Mengxiao Li, Yanwu Fan, Pingyu Shi, Ziwei Wang, Wei Su, Haijun Wang. Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer. European Journal of Pharmacology 2024; 967 doi: 10.1016/j.ejphar.2024.176357
|
| 24 |
Florentine E. F. Timmer, Bart Geboers, Sanne Nieuwenhuizen, Madelon Dijkstra, Evelien A. C. Schouten, Robbert S. Puijk, Jan J. J. de Vries, M. Petrousjka van den Tol, Anna M. E. Bruynzeel, Mirte M. Streppel, Johanna W. Wilmink, Hans J. van der Vliet, Martijn R. Meijerink, Hester J. Scheffer, Tanja D. de Gruijl. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers 2021; 13(16) doi: 10.3390/cancers13164138
|
| 25 |
Inga Hochnadel, Uta Kossatz-Boehlert, Nils Jedicke, Henrike Lenzen, Michael P. Manns, Tetyana Yevsa. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Human Vaccines & Immunotherapeutics 2017; 13(12) doi: 10.1080/21645515.2017.1359362
|
| 26 |
Wen Zhang, Xu Lu, Peilin Cui, Chunmei Piao, Man Xiao, Xuesong Liu, Yue Wang, Xuan Wu, Jingwei Liu, Lin Yang. Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunology, Immunotherapy 2019; 68(1) doi: 10.1007/s00262-018-2257-2
|